A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia (NCT07623200)

🧪 Interventions in This Study

• INCA033989 (DRUG)
• Best Available Treatment (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (180 Sites)

Showing the first 25 of 180 sites.

• Banner Md Anderson Cancer Center — Gilbert, Arizona
• The University of Arizona Cancer Center — Tucson, Arizona
• City of Hope Medical Center — Duarte, California
• Marin Cancer Care — Greenbrae, California
• University of California, Los Angeles Medical Center — Los Angeles, California
• Stanford Cancer Center — Palo Alto, California
• UCSF — San Francisco, California
• Rocky Mountain Cancer Centers-Lone Tree — Lone Tree, Colorado
• Medstar Georgetown Medical Center, Inc — Washington D.C., District of Columbia
• Florida Cancer Specialists & Research Institute — Fort Myers, Florida
• University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
• Cleveland Clinic — Weston, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
• University of Chicago — Chicago, Illinois
• The University of Kansas Cancer Center — Westwood, Kansas
• Johns Hopkins Medicine-the Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
• Maryland Oncology Hematology, P.A. — Columbia, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Beth Israel Deaconess Medical Center (Bidmc) — Boston, Massachusetts
• University of Massachusetts Medical School — Worcester, Massachusetts
• University of Michigan Rogel Cancer Center Adult Bone Marrow Transplant Clinic — Ann Arbor, Michigan
• Missouri Cancer Associates — Columbia, Missouri
• Washington University School of Medicine — St Louis, Missouri
• John Theurer Cancer Center, Hackensack University Medical Center — Hackensack, New Jersey

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Essential Thrombocythemia

• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) — Glendale, Arizona
• A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET — Birmingham, Alabama
• Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance — Scottsdale, Arizona
• IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) — Miami, Florida
• A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) — Glendale, Arizona
• Ruxolitinib in Thrombocythemia and Polycythemia Vera — Boston, Massachusetts

Explore by condition: All Essential Thrombocythemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.